135 results on '"Abu-Khalaf, M"'
Search Results
2. PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine
3. Early Islamic wood work in Egypt and the Fertile Crescent
4. Preoperative Ultrasonography and Prediction of Technical Difficulties during Laparoscopic Cholecystectomy
5. Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer
6. Abstract P3-01-19: HER2-positive circulating tumor cells (CTCs) in advanced breast cancer (BC): A feature independent of BC subtype
7. Abstract P2-09-08: Imprime PGG, a novel innate immune modulator, combined with pembrolizumab in a phase 2 multicenter, open label study in chemotherapy-resistant metastatic triple negative breast cancer (TNBC)
8. Abstract OT2-06-04: MORPHEUS: A phase Ib/II trial platform evaluating the safety and efficacy of multiple cancer immunotherapy combinations in patients with hormone receptor–positive and triple-negative breast cancer
9. Abstract P5-17-02: Dissecting the biology of inflammatory breast cancer (BC) through cell free DNA and a circulating tumor cells (CTC)-derived signature
10. Abstract P5-17-03: How is inflammatory breast cancer (IBC) different? Integration of clinico-pathological features and circulating tumor cells (CTCs)-based biomarkers for disease and prognostic assessment
11. Abstract P2-05-06: Not presented
12. Abstract P6-11-03: A phase 2 open-label study of lucitanib in patients (pts) with FGF aberrant metastatic breast cancer (MBC)
13. Abstract P1-05-09: Association of co-amplicons with immune infiltration in subtypes of HER2-Positive breast cancer
14. Abstract P6-03-08: Novel recurrent lncRNA fusions detected in breast cancer using RNA-Seq technology in a neoadjuvant setting
15. Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):2916-21. doi: 10.1073/pnas.1222577110. Epub 2013 Jan 28. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Zhao S1, Choi M, Overton JD, Bellone S, Roque DM, Cocco E, Guzzo F, English DP, Varughese J, Gasparrini S, Bortolomai I, Buza N, Hui P, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Carrara L, Pecorelli S, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Stiegler AL, Mane S, Boggon TJ, Schlessinger J, Lifton RP, Santin AD
16. Environmental impacts assessment and horizons of rehabilitation of abandoned limestone quarries: a case study from the Southern part of the West Bank
17. Adaptive optimal control for continuous-time linear systems based on policy iteration
18. Abstract P6-06-37: Predicting improvements in survival based on improvements in pathologic response rate to neoadjuvant chemotherapy in different breast cancer subtypes
19. Abstract P1-08-16: Deep sequencing of breast tumor biopsies reveals an association between pathologic complete response and reduction of TP53 clonal abundance upon brief exposure to therapy
20. Abstract P4-04-02: RNA-seq reveals functional lncRNAs associated with estrogen-receptor status in breast cancer
21. Abstract P4-04-07: Heterogeneous gene fusions detected by RNASeq show enrichment of insulin signaling pathway genes in breast cancer
22. Abstract P2-11-22: The use and influence of a 21 gene rearrangement assay in breast cancer: Clinical and pathologic predictors of recurrence score and chemotherapy receipt
23. Abstract P4-01-02: Association of DCE-MRI texture features with molecular phenotypes and neoadjuvant therapy response in breast cancer
24. Abstract PD05-05: RNA-seq identifies unique transcriptomic changes after brief exposure to preoperative nab-paclitaxel (N), bevacizumab (B) or trastuzumab (T) and reveals down-regulation of TGF-β signaling associated with response to bevacizumab
25. Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy
26. دراسة عودة نمو العصب الحائر بعد عملية قطع أفرع العصب الفائقة الانتقاء باستخدام التصوير الاشعاعي الذاتي
27. P3-06-01: Next Generation RNA Sequencing Reveals Changes in Gene Expression and Alternative Splicing upon Brief Exposure to Therapy in Early Breast Cancer.
28. P3-06-04: Sno/miRNA Expression Via Next Generation Sequencing: Variation in Patients before and after Treatment.
29. A phase I study of biweekly capecitabine and the histone deacetylase inhibitors (HDACi) vorinostat in for advanced breast cancer (BC).
30. A phase I clinical trial of the mTOR inhibitor everolimus in combination with oral topotecan for patients with recurrent and advanced endometrial cancer
31. Retrospective analysis of elderly patients (pts) with primary epithelial ovarian cancer (EOC) age 70 or older.
32. Cisplastin (C) and ifosfamide (I) chemotherapy with vaginal cuff brachytherapy (VCBT) for treatment of uterine carcinosarcoma.
33. A phase I study of the mTOR inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel (nab-P).
34. In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma
35. A phase I study investigating the combination of orally bioavailable platinum and nanoparticle albumin-bound paclitaxel in advanced solid tumors
36. Parameterization of all stabilizing [formula omitted] static state-feedback gains: Application to output-feedback design
37. Discrete-Time Nonlinear HJB Solution Using Approximate Dynamic Programming: Convergence Proof
38. Parameterization of all stabilizing H∞ static state-feedback gains: Application to output-feedback design
39. Parameterization of All Stabilizing Hc. Static State-Feedback Gains: Application to Output-Feedback Design
40. Neoadjuvant dose-dense (DD) concurrent doxorubicin (A) and docetaxel (T) for stage III breast cancer (BC)
41. Quantitative image analysis of VEGF expression on a breast cancer tissue microarray
42. High expression of the chemokine receptor CCR7 is associated with worse outcome in breast cancer
43. A Hamilton-Jacobi setup for constrained neural network control
44. Model-free Approximate Dynamic Programming Schemes for Linear Systems.
45. Continuous-Time ADP for Linear Systems with Partially Unknown Dynamics.
46. A Neural Network Solution for Fixed-Final Time Optimal Control of Nonlinear Systems.
47. Hereditary thrombophilia among 217 consecutive patients with thromboembolic disease in Jordan
48. In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma.
49. Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013.
50. Adrenal Cysts: Diagnosis and Management
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.